Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development
نویسندگان
چکیده
We conducted a comprehensive analysis of clinical pharmacology evaluations in initial submissions of 56 oncology new molecular entities approved by the US Food and Drug Administration between January 2011 and April 2017. Results from studies evaluating food effect, QTc prolongation, drug-drug interactions, renal and hepatic impairment effects, and dose optimization, as well as postmarketing requirements/commitments, were reviewed. This reverse translational research highlights the importance of clinical pharmacology and pharmacometrics in benefit-risk characterization, regulatory review, and labeling of anticancer therapeutics.
منابع مشابه
Lessons learned from the use of ESAs.
Dr. Bennett and colleagues have provided a thorough and balanced history of the rise and fall of erythropoietin-stimulating agents (ESAs) in cancer-associated anemia. Their review encourages us to think about the lessons learned from this history—lessons about medical progress, the importance of clinical research in guiding clinical practice, and the role of the US Food and Drug Administration ...
متن کاملUltimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
PURPOSE To approve a new anticancer drug, the US Food and Drug Administration often requires randomized trials. However, several oncology drugs have been approved on the basis of objective end points without a randomized trial. We reviewed the long-term safety and efficacy of such agents. METHODS We searched the Web site of the US Food and Drug Administration's Center for Drug Evaluation and ...
متن کاملPlanning and Budgeting for Nutrition Programs in Tanzania: Lessons Learned From the National Vitamin A Supplementation Program
Background Micronutrient deficiency in Tanzania is a significant public health problem, with vitamin A deficiency (VAD) affecting 34% of children aged 6 to 59 months. Since 2007, development partners have worked closely to advocate for the inclusion of twice-yearly vitamin A supplementation and deworming (VASD) activities with budgets at the subnational level, where funding and implementation o...
متن کاملImmuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
Background IPI (Yervoy, Bristol-Myers Squibb) blocks cytotoxic Tlymphocyte antigen-4, a regulatory molecule on activated T cells. In March 2011, IPI, indicated for unresectable or metastatic melanoma (MEL), became the first immune checkpoint inhibitor approved by the US Food and Drug Administration (FDA). Early in development, severe and fatal immune-related adverse events (irAEs) emerged and w...
متن کاملEconomics of new oncology drug development.
PURPOSE Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development. METHODS We utilized data from the US Food and Drug Administration (FDA), company surveys, and publicly available commercial business intelligence databases on new oncology drugs approved in the United States and on investigational oncology drugs to estim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2018